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Translational relevance 
The effect of targeted therapy on intratumoral heterogeneity has not been studied in renal cancer. 
We report a study using a unique set of sunitinib naïve and treated clear cell renal cancer samples 
from patients with metastatic disease enrolled in clinical trials. There was significant 
intratumoral heterogeneity at protein, mRNA and DNA levels. Following sunitinib therapy there 
was increased intratumor heterogeneity of tumor grade, renal cancer driver gene mutations 
(mRNA and DNA) and protein expression. Despite this, consistent genetic alterations to key 
renal cancer genes occurred following sunitinib therapy. These results suggest that the 
commonly proposed mechanism of drug treatment enforcing clonal selection of a pre-existing 
clone should be reconsidered. Instead it appears that the tumor is becoming molecularly more 
complex, which concurs with the increased clinical difficulty in treating patients who have 
developed resistance to first-line targeted therapy.  
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Abstract:  
Purpose: The aim of this study was to investigate the effect of VEGF targeted therapy 
(sunitinib) on molecular intratumoral heterogeneity (ITH) in metastatic clear cell renal cancer 
(mccRCC).  
Experimental design: Multiple tumor samples (n=187 samples) were taken from the primary 
renal tumors of mccRCC patients who were sunitinib treated (n=23, SuMR clinical trial) or 
untreated (n=23, SCOTRRCC study). ITH of pathological grade, DNA (aCGH), mRNA 
(Illumina Beadarray) and candidate proteins (reverse phase protein array) were evaluated using 
unsupervised and supervised analyses (driver mutations, hypoxia and stromal related genes). ITH 
was analysed using intratumoral protein variance distributions and distribution of individual 
patient aCGH and gene expression clustering.   
Results: Tumor grade heterogeneity was greater in treated compared to untreated tumors 
(P=0.002). In unsupervised analysis, sunitinib therapy was not associated with increased ITH in 
DNA or mRNA. However, there was an increase in ITH for the driver mutation gene signature 
(DNA and mRNA) as well as increasing variability of protein expression with treatment 
(p<0.05). Despite this variability, significant chromosomal and transcript changes to key targets 
of sunitinib, such as VHL, PBRM1 and CAIX, occurred in the treated samples.  
Conclusions: These findings suggest that sunitinib treatment has significant effects on the 
expression and ITH of key tumor and treatment specific genes/proteins in mccRCC. The results, 
based on primary tumor analysis, do not support the hypothesis that resistant clones are selected 
and predominate following targeted therapy.  
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Introduction 
A number of targeted agents are available for the treatment of metastatic clear cell renal cell 
cancer (mccRCC), of which a VEGF tyrosine kinase inhibitor (TKI), sunitinib, is most 
prominent (1). Clinical benefit with sunitinib varies between mccRCC patients, however 
resistance usually develops within a year in all patients. Unlike some other tumors (2), the 
mechanism of TKI resistance in mccRCC is unclear.  
Recent analysis of primary and metastatic RCC tissue showed significant DNA 
intratumoral heterogeneity (ITH), driving the hypothesis that a process of clonal evolution occurs 
within RCC (3,4).  Theoretically the presence of ITH is relevant in the development of resistance 
to VEGF targeted therapy. It is hypothesised that one of two possible scenarios occurs in 
resistance to targeted therapy: (i) a single resistant clone, potentially present at baseline, 
predominates during resistance resulting in reduced ITH with therapy; or (ii) a multifactorial 
process of acquired polyclonal resistance occurs, in which there is an initial increase in ITH with 
the potential for development of multiple resistant clones (5).    
To evaluate the effect of TKIs on ITH and provide further evidence regarding likely 
mechanisms of resistance to targeted therapy, multiregion tissue sampling and DNA, RNA, 
protein expression analysis was performed on a cohort of primary ccRCC tumors from sunitinib 
naïve and treated mccRCC patients to identify if: (i) molecular heterogeneity also occurred at a 
RNA and protein level; and (ii) a period of sunitinib treatment (18 weeks) exacerbated molecular 
heterogeneity. Ideally, to answer the latter question one would undertake multi-region tumor 
sampling both before and after the sunitinib treatment, but before nephrectomy. Such an 
experiment would not be ethical or permissible. As such, we used a comparator group in the 
form of patients with well-matched sunitinib naïve tumors. Sunitinib has specific molecular 
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targets and has an effect on stromal elements within the tumor (4,6). It is conceivable that whilst 
sunitinib has little effect on ITH of the whole genome it may have specific effects on drug targets 
and driver mutations. Also, sunitinib may have inconsistent effects on the ITH of different 
components of the tumor, e.g. increased ITH may be solely due to increased variability of host 
response to the drug in stromal elements (such as variable lymphocyte infiltration (4)), rather 
than direct changes to variability of tumor clones. As such, we hypothesised that sunitinib 
treatment results in an increase in ITH of treatment specific genes, due to treatment related 
pressure. Therefore, in addition to unsupervised analysis, supervised analysis was undertaken for 
ITH in genes associated with: (i) key driver mutations in renal cancer; (ii) stromal elements; and 
(iii) molecular (mainly hypoxia related) targets of sunitinib. Understanding the effect of therapy 
on ITH gives insight into mechanisms of drug resistance and facilitates future biomarker work 
and drug development.   
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Methods 
 
Patients and samples 
Adequate fresh frozen primary ccRCC tissue for analysis was obtained from the cytoreductive 
nephrectomy samples of 23 sunitinib naive mccRCC patients as part of the Scottish 
Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC) study (UK CRN 
ID: 12229). Fresh frozen primary tumor tissue was also obtained from 27 mccRCC patients 
treated with 3 cycles of sunitinib (18 weeks) followed by a cytoreductive nephrectomy after 2 
weeks off sunitinib as part of the Upfront Sunitinib (SU011248) Therapy Followed by 
Surgery in Patients with Metastatic Renal Cancer: a Pilot Phase II Study (SuMR; 
ClinicalTrials.gov identifier: NCT01024205); 23 of these patients had adequate tissue for 
analysis. Investigations were approved by institutional review boards and written, informed 
consent was obtained from each patient 
  
Tissue Mapping 
Tissue was obtained from at least three spatially separate regions of the kidney tumor (more 
regions if the size of the tumor allowed). Tissue processing was then performed as previously 
described (7). Briefly, if required each piece of tumor tissue was mapped and divided into 
smaller pieces (~1cm3) in preparation for lysate creation. A cryostat section was performed on 
each 1cm3 piece of tissue to confirm the presence of viable ccRCC and for grading (low grade, 
high grade or mixed low/high grade) by 2 independent histopathologists (MO, DB). A minimum 
of four protein/DNA/RNA lysates were aimed for per patient, from each morphologically 
differing region within each tumor.  
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Nucleic acid/protein extraction from tissue  
(i) Nucleic acid 
DNA extraction from fresh frozen tissue was carried out using the DNeasy Blood and Tissue Kit 
(Qiagen, UK) according to the manufacturer’s instructions. The only significant alternation to the 
standard protocol was the addition of a PBS washing step to remove OCT compound carried 
over from the process of producing cryostat sections. Samples were fragmented prior to 
proteinase K digestion using a Qiagen Tissue Lyser. aCGH hybridisation was carried out as 
described (8).  
RNA extraction was carried out using miRNEasy Kit (Qiagen, UK) according the 
manufacturer’s protocols. Amplification and analysis of the RNA was as previously described 
(9).  
 
(ii) Protein 
50-75mg of tissue was placed into 2ml tubes with 990μl of lysis buffer (50mM Tris–HCl (pH 
7.5), 5mM EGTA (pH 8.5), 150mM NaCl) supplemented with aprotinin (10mg/mL), 
phosphatase inhibitor cocktail A (Sigma, UK), phosphatase inhibitor cocktail B (Sigma, UK) and 
a protease inhibitor cocktail (Roche, UK). A single 5mm steel ball was added to each tube and 
the samples were homogenised at 50Hz twice for 5 minutes using a TissueLyser (Qiagen, UK). 
10μl of Triton X-100 was added to each sample before centrifuging at 13,000g for 30 min at 4°C 
after which supernatants were transferred to fresh microcentrifuge tubes. Total protein 
concentrations were determined by BCA assay (Sigma, UK) and normalised to 1mg/mL.  
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Array-based comparative genomic hybridisation  
aCGH hybridisation and analysis was carried out as recently described (8) using Roche UK 
Nimblegen 12X135k whole-genome array. The CGH-segMNT module of NimbleScan was used 
for the analysis with a minimum segment length of five probes and an averaging window of 
130kb. Nimblegen arrays were positionally annotated based upon hg19 genomic coordinates and 
log ratio data was pre-processed in R as previously described (10). Briefly, array data was 
normalised with print tip Loess from the limma package to produce normalised log ratios, 
filtered to remove outliers based upon a 1 MAD deviation of each probe from its immediate 
genomic neighbours and smoothed with a circular binary segmentation algorithm from the 
DNACopy package. Smoothed log ratios were then thresholded for gain/loss (±0.1) and 
amplification/deletion (±0.45) to identify contiguous copy number aberrations containing at least 
15 consecutive probes. For clustering categorical aCGH states representing gain, loss, 
amplification and deletion were clustered based upon Euclidean distance using a Ward’s 
algorithm using the segmented values from the whole genome in each case. aCGH data available 
via GEO (Accession number GSE67818). 
 
VHL genotyping 
VHL genotyping (East of Scotland Regional Molecular Genetics Service, Ninewells Hospital, 
Dundee, UK) included sequence analysis of exons 1-3 of the VHL gene to detect mutations in 
the coding region plus multiplex ligation-dependant probe amplification for large deletions. 
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Gene expression analysis 
mRNA was amplified using the WT-Ovation FFPE System Version 2 (NuGEN, UK), purified 
using the Qiaquick PCR Purification Kit (Qiagen, UK), biotinylated using the Encore BiotinIL 
ModuleIL  (NuGEN, UK), purified using minElute Reaction Cleanup Kit (Qiagen, UK) and 
quantified using a Bioanalyser 2100 with RNA 6000 Nano Kit (Agilent, UK). cRNA was then 
hybridised to Human HT-12v3 expression Beadarrays (Illumina, Cambridge, United Kingdom) 
according to the standard protocol for NuGEN amplified samples. Gene expression data was read 
and normalised with the lump package in R using variance stabilisation and robust spline 
normalisation. Illumina expression data was annotated based upon ensembl gene annotation 
(hg19, release 61). Processed data was filtered to remove probes flagged as undetected in more 
than 50% of the 192 samples analysed and probes with replicate gene identifiers were removed 
selecting those with the highest variance for each gene. For unsupervised clustering the most 
informative probes were selected as those with a median absolute deviation across the dataset of 
greater than 0.6 leaving an intrinsic dataset representing 1787 probes from unique genes. Filtered 
expression data was then clustered based upon Euclidean distance using a Ward’s algorithm. 
Gene expression data available via GEO (Accession number GSE65615). 
 
Supervised copy number variation (CNV) and gene expression analysis 
Supervised analysis was performed in order to assess clustering of individual patient tumor DNA 
and mRNA samples and CNV or differential gene expression with respect to molecules of 
relevance in renal cell cancer: (a) key molecular targets of sunitinib and hypoxia related genes; 
(b) stromal associated genes (extracellular matrix, stromal remodelling, and adhesion molecules) 
were utilised as previously described (11); and (c) a driver mutation gene set which was derived 
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from those genes mutated in greater than 3% of the cases in the TCGA renal clear cell dataset. 
For ordered clustering treatment groups were ordered according to the number of copy number 
changes in each case from left to right in the aCGH figures and for the mean total expression of 
all the genes in the list in the expression heat maps. 
 
Reverse phase protein arrays (RPPA) 
RPPA samples protein levels were determined and slides spotted as described previously (7,12). 
Briefly, batch effects across the three slides per marker were mitigated using ComBat (13) and 
normalized (VSN (14)). 58 proteins making up key functional groups of proteins in RCC 
pathogenesis or sunitinib response were selected for study (tables S1&S2). There was no signal 
detected for three of the proteins (Ki67, FLT3 and phospho-Jak2), leaving 55 proteins for 
analysis (antibodies detailed in table S1).  
 
Statistical analysis  
As described previously, aCGH (15) and gene expression (10) cluster dendrograms were created 
and cut into 30 branches, those patients whose tissue samples all fell within the same branch 
were defined as clustered. Heterogeneity was assigned where an individual patient’s samples 
were split between two or more clusters within the dendrogram.  
Intratumoral protein variance was calculated separately for untreated and sunitinib treated 
patients in an ANOVA framework. Untreated and treated variance distributions combining data 
from all 55 proteins were compared by a Mann-Whitney test (MW). Intratumoral variances for 
individual proteins were compared by an F-test where assumptions of normality and 
homoscedasticity held, respectively assessed using the Lillefours and Fligner tests; false 
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discovery rate (FDR) correction was applied (16). Differential protein expression between 
untreated and treated patient samples was tested for each protein using a Student t-test where 
normality and homoscedasticity assumptions were met, otherwise MW was performed; FDR was 
applied over combined t-test and MW values (16).  
The MW/t-test and chi-square test/Fisher’s exact test were used to test differences in 
continuous variables and categorical variables between the 2 groups, respectively. Pearson’s 
correlation coefficient was used to calculate correlation using non-parametric data. P-values of 
<0.05 were taken as significant and all P-values were two-tailed. SPSS version 21 (IBM 
Corporation, Armonk, NY) or the R package (version 2.11.1) was used for all statistical 
analyses. 
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Results  
 
Patient demographics 
Of the 50 patients included in this study there was adequate tissue for analysis from 46 patients. 
The characteristics and clinical outcomes of the two patient cohorts (sunitinib treated and 
untreated) are given in table 1; the two groups were comparable other than for tumor grade (see 
below). Multiple tissue samples were obtained for all patients (total=187 samples). The precise 
number of replicate samples for analysis from each patient was driven by the specific availability 
of tissue. Multiple protein lysates were obtained from 44 patients (median 4 regions, (range 2-10 
regions)). Multiple DNA lysates were obtained from 42 patients (median 3 regions (range 2-5 
regions)). Multiple RNA lysates were obtained from 36 patients (median 3 regions (range 2-8 
regions)).  
 
Morphological heterogeneity of sunitinib naive and treated mccRCC samples 
Tumor grade was assessed in multiple regions from each tumor to assess ITH (table 1). A 
homogeneous grade (tumor contained either low or high grade, but not both grades) occurred in 
26 (57.8%) samples while heterogeneous grading (tumors containing both low and high grade 
elements) occurred in 19 (42.2%). Significantly more treated tumors expressed morphological 
heterogeneity compared to untreated tumors (65.2% vs 18.2%; P=0.002).  
 
Unsupervised aCGH analysis to assess global genetic instability and ITH   
Comparison of aCGH results, from multiple DNA samples, taken from spatially different areas 
of each tumor showed variable intratumoral clustering (table 2). In sunitinib naive tumors, 23/67 
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(34.3%) patient DNA samples clustered compared with DNA from 25/61 (41.0%) sunitinib 
treated samples (P=0.44, fig. 1A), suggesting substantial underlying genetic ITH in mccRCC 
primary tumors which was not significantly altered by sunitinib. Although the extent of ITH did 
not alter with sunitinib, there were significantly greater levels of chromosomal gains, 
amplifications and deletions in treated compared with untreated samples (p<0.03) (fig. 1B).  
 
Unsupervised gene expression analysis to determine global transcriptomic ITH 
Hierarchical clustering of gene expression results from multiple RNA samples from each tumor 
showed that there was intratumor clustering in 24/36 patients (fig. 1C & table 2). There was a 
greater proportion of patients whose RNA clustered compared with DNA clustering (table 2) 
24/36 (67%) vs 17/42 (40.5%) patients respectively (p=0.025). As with the DNA analysis, there 
was comparable intratumoral clustering of untreated patient RNA samples, 26/43 (60.5%) RNA 
samples, compared with, 48/73 (65.8%) RNA samples from treated patients, P=0.69.  
 
Correlation of sample clustering for DNA and gene expression  
There were 33 patients with clustering results available for both DNA and RNA. Eight patients 
(24.2%) had both DNA and RNA samples which clustered, 17 patients (51.5%) had either RNA 
or DNA which clustered and in 8 patients (24.2%) neither RNA nor DNA was determined to 
have clustered. Clustering of either DNA or RNA made clustering in the other nucleic acid more 
likely (P=0.015). 
 
Effect of sunitinib treatment on intratumor protein heterogeneity and protein expression 
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Intratumoral variance in expression of candidate proteins, measured using RPPA, was marked in 
untreated patient samples (fig. 2A). But protein variance was even higher in the sunitinib treated 
samples compared to the untreated samples (40/55, P=0.001; fig. 2B). Despite exacerbation of 
protein variance by sunitinib, there were significant differences in median expression of 30 of the 
55 proteins evaluated (table S2). There was no correlation of the effect of sunitinib on 
differential RNA and protein expression (fig. S1). Consistent, significant changes for both 
mRNA and protein were only seen for 1 of the 55 proteins evaluated (Cyclin D1).   
 
Supervised aCGH and gene expression analysis to assess ITH of relevant pathways 
Three key groups of genes, relevant in renal cancer pathogenesis and TKI treatment were 
assessed to observe for ITH and to assess which tumor component may be driving protein ITH 
following sunitinib therapy. Key driver mutations, hypoxia associated genes and stroma related 
genes were assessed for aCGH derived CNVs (table 2 & fig. S2) and gene expression analysis 
(table 2 & fig. S2). Considering CNVs, there was a significant reduction in individual patient 
sample clustering of driver mutation (P=0.032) and hypoxia genes (P<0.001) in treated patients, 
suggesting increased ITH.  
For gene expression analysis clustering, driver mutation genes, hypoxia and stroma 
associated genes had less clustering in treated samples than untreated patient samples (table 2 & 
fig. S2); this reduction in clustering was significant for driver mutation (p=0.006) and stroma 
associated genes (P=0.016) but not hypoxia genes (P=0.29).  
 
Differential copy number variation and gene expression between untreated and treated 
patients 
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Comparison of untreated and treated DNA samples revealed the significant gains or losses in the 
region of the following key genes (fig. 3). In the treated samples there were gains of VEGFR3 
and PDGFRβ and losses for VCAM1, HIF1α, CAIX, mTOR, BAP1, PBRM1, SETD2 and VHL. 
Of note, no significant CNVs were seen to VEGFR2 (KDR).  
Similarly, gene expression profiles of untreated and treated patient tumor RNA samples 
were compared (fig. 4). Vimentin, clusterin, PDGFα, PDGFβ, VEGFA, VEGFR2 (KDR), HIF1α 
and CAIX all had significantly greater expression in treated tumor samples. PBRM1, KDM5C, 
VHL and PDGFC had significantly lower levels of expression in the treated samples.   
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Discussion  
Initially we showed that primary ccRCC tissue from patients treated with sunitinib expressed 
greater morphological heterogeneity (of tumor grade) compared to tumors from untreated 
patients. This was intriguing and, in view of the similar characteristics of the patient cohorts, was 
postulated to be treatment rather than patient related. These findings built on our previous 
findings from paired, sequential biopsy and nephrectomy samples which showed that sunitinib 
therapy was associated with increased tumor grade, lymphocyte infiltration and proliferation (Ki-
67 expression) (4). This increase in pathological ITH prompted further investigation at the 
molecular level to determine if sunitinib treatment was associated with dynamic molecular 
changes resulting in a more aggressive tumor phenotype. There has been extensive work on 
DNA heterogeneity at a single time point, resulting in the hypothesis of specific somatic 
mutations, following a pattern of clonal evolution (3). In the work presented above it was 
hypothesised that sunitinib treatment results in an increase in ITH of treatment specific genes, 
due to treatment related pressure; such clonal divergence may facilitate the evolution of resistant 
phenotypes.  
In order to test the hypothesis, we performed chromosomal, RNA and protein based 
analyses. Results identified ITH at every molecular level investigated, in both treated and 
untreated samples. A comparison of mRNA and DNA results showed less ITH at a transcript 
level, suggesting ITH was predominantly genetic. Overall, approximately only half of multiple 
DNA or mRNA samples from individual tumors clustered together demonstrating the extent of 
the ITH. As has been previously demonstrated (17), there was remarkable inconsistency 
regarding mRNA and protein expression in both treated and untreated samples. Cyclin D1 was 
the only molecule for which a mRNA-protein correlation was found, potentially suggesting it for 
Research. 
on June 5, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 26, 2015; DOI: 10.1158/1078-0432.CCR-15-0207 
 18
future multi-level molecular analysis. Despite this, there was a positive correlation between 
tumors with both DNA clustering and mRNA clustering, suggesting some consistency within 
tumors at different levels of molecular analysis. Therefore the process of ITH was not purely 
random or molecular technique specific, but individual tumors appeared to have different 
degrees of ITH, which was consistent across DNA and mRNA.  
The effect of VEGF treatment on ITH at a molecular level is unknown in renal cancer. 
Indeed, to our knowledge there is an absence in the literature for any tumor type. Unsupervised 
analysis did not reveal any significant effect of sunitinib therapy on ITH at a chromosomal or 
mRNA level. This finding may have been expected as sunitinib has specific effects and is 
therefore unlikely to affect the whole genome significantly. However, results from supervised 
analyses showed a consistent increase in ITH for both DNA and mRNA of the renal cancer 
driver mutation genes. The degree of DNA and RNA ITH of stromal and hypoxia related genes 
following sunitinib therapy was inconsistent. The consistent increase in ITH in the driver 
mutations and the lack of consistent results in the stromal genes suggests that the findings are, at 
least in part, tumor related rather than purely stromal related reactions to therapy. Our results 
suggest dynamic changes to heterogeneity in the tumor, vascular and stromal components may 
be distinct with sunitinib. Whether changes to specific genetic alterations/expression are due to 
direct effects of treatment on the tumor or indirect effects on the tumor/stroma ratio remain 
uncertain. These findings were supported by protein expression results where an increase in ITH 
was observed for selected tumor specific proteins. It is conceivable that sunitinib causes 
diversification of protein expression within tumors as a reaction to treatment associated factors 
such as hypoxia, as postulated previously for other tumors (18). 
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The relatively short period of targeted treatment (18 weeks), consistent time between 
cessation of sunitinib and nephrectomy and the significant changes to selected relevant targets 
indicate that the exacerbated ITH in treated samples is likely to be treatment related rather than 
simply time related.  
These results allow the development of further hypotheses regarding the mechanism of 
acquired resistant to VEGF targeted therapy in mccRCC. The findings presented here do not 
support the hypothesis that a single resistant clone predominates from a number of clones after 
treatment commences, as treatment was associated with more rather than less ITH. As such, it 
can be speculated that there may be an expansion of clones, facilitating the development of 
resistant clones, that is polyclonal drug resistance (5). Further work using circulating samples or 
multiple biopsies at multiple time points throughout drug treatment would be required to prove 
the development of polyclonal drug resistance and allow the development of clinically relevant 
strategies to overcome drug resistance 
These findings may be relevant in optimizing the timing of immune checkpoint inhibitors 
in metastatic RCC. These therapies may work best in tumors with a high mutational burden (19). 
Therefore starting checkpoint inhibitor therapy after a short period of VEGF targeted therapy, 
when mutational burden may be higher is attractive. This approach should be considered for 
future clinical trials.  
The final finding was that despite ITH, consistent chromosomal, RNA and protein 
changes to the targets of sunitinib were seen with treatment, in keeping with our previous 
findings regarding consistent changes in CAIX protein expression following sunitinib treatment 
(12). Notable CNVs identified were losses of the renal cancer driver genes SETD2, BAP1, VHL 
and PBRM1 (latter two genes also had a significantly lower level of gene expression) following 
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sunitinib therapy (20). BAP1 and PBRM1 loss have previously been shown to be associated with 
a poor prognosis (21). It should be noted that, together with greater levels of 3p loss in the 
treated patient cohort, enrichment of the 3p tumor suppressors maybe due to intrinsic differences 
in the unmatched patient cohorts rather than treatment; although this is thought to be unlikely 
due to the comparable VHL mutation rate of 78% in the untreated patients and 65% in the treated 
patients. Overall, these genetic alterations suggests that sunitinib is having direct effects on the 
tumor and further supports the hypothesis that the changes seen with sunitinib are not purely a 
time related phenomena.  
 We recognize the limitations of this study. Firstly, although the characteristics of the two 
groups were similar, the treated and untreated samples frozen were not matched from the same 
patients. However, obtaining multiple frozen samples from nephrectomy patients is challenging, 
requiring close interaction between urologists and pathologists (22); the multi-region sample set 
described here is to our knowledge the largest available. The ideal validation set of matched pre- 
and post-treatment multiregion sampled tumors is not feasible or ethical and a similar validation 
cohort to ours was unavailable. However, the multilevel analysis performed in this study, with all 
analyses confirming increasing ITH with treatment, acts as internal validation of the conclusions. 
Secondly, there was a two-week break between sunitinib completion and nephrectomy, which 
may have influenced the results in the treated patients. Finally, sunitinib was given for a fixed 
period and responses to sunitinib were variable. Therefore treated samples may have been at 
different stages of clonal evolution. Finally, there is a justified concern that identification of 
specific tumor related results might be contaminated by treatment-induced changes to the 
proportion of the stromal component within the tumor. The supervised analysis presented in this 
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study attempted to address this concern; however, this is a consideration when interpreting the 
data presented. 
 The results of this study demonstrate a more complex tumor appears to be developing 
following sunitinib therapy. The resulting tumor is likely to be difficult to target successfully 
using a ‘one size fits all approach’ as is currently standard of care in VEGF-targeted therapy 
resistant disease. These findings may in part explain why treatment in relapsed disease is 
particularly challenging (23).  
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Figure legends:  
Fig. 1. Unsupervised aCGH and gene expression clustering results. (A) Heatmap 
demonstrating clustering of aCGH profiles of sunitinib naive and treated samples. Categorical 
aCGH states (i.e. gains, losses, and amplifications) were used for clustering, employing Ward’s 
clustering algorithm based upon Euclidean distance. No significant difference in aCGH 
clustering was seen between treated and untreated patients (P=0.44; Fisher’s test). (B) 
Comparisons of the number of aCGH aberrations in treated and untreated samples showed 
significantly more copy number gains, amplifications and deletions in treated patients than in 
untreated patients (t-test). (C) Heatmap demonstrating unsupervised clustering of gene 
expression profiles of sunitinib naive and treated samples. Filtered gene expression data was 
clustered based upon Euclidean distance using a Ward’s algorithm. There were no significant 
difference in sample clustering between treated and untreated patients (P=0.69; Fisher’s test). 
Heatmap is a representation of all probes, created using clusters containing treatment related 
genes and those driving the dendrogram. 
Fig. 2. Protein results for sunitinib naive and treated samples. (A) Histogram demonstrating 
the intratumoral variance for each of the 55 proteins analysed with RPPA in sunitinib naive 
patients. (B) log2 within tumor variance ratio of sunitinib naive and treated samples. The number 
of proteins analysed for which the median intratumoral variance is greater in the sunitinib naive 
group (n=15); greater in the sunitinib treated group (n=40). There are significantly more proteins 
with higher median variance in the treated group than the untreated group (P=0.001, binomial-
test). Proteins with variance below zero on y-axis are greater for the untreated primary tumor, 
those above the y-axis zero were greater in the treated primary tumor. Table S2 details the 
differential protein expression seen following sunitinib therapy. 
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Fig. 3. Supervised analysis of driver mutation, hypoxia and stromal molecules copy number 
variation between untreated and treated patients. Heat maps (A) driver mutations, (B) 
hypoxia and (C) stroma plotting gains/amplifications (red) and losses/deletions (blue) in 
corresponding gene regions. The right-hand bar represents the lod score (-log10) of the adjusted 
P-value (Fisher’s test), dashed line represents P=0.05, bars are colored when significant (red, 
significant gain in treated patient samples; blue, significant loss in treated patient samples). The 
genes regions are ordered according by level of significance. 
Fig. 4. Supervised analysis of driver mutation, hypoxia and stromal molecules gene 
expression between untreated and treated patients. Heat maps for gene expression levels of 
(A) driver mutations, (B) hypoxia and (C) stromal related genes. The right-hand bar represents 
the lod score (-log10) of the adjusted P-value (t-test), dashed line represents P=0.05, bars are 
colored when significant (red, greater expression in treated patient samples; blue, lower 
expression in treated patient samples). The genes are ordered according to the level of 
significance. 
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Table 1. Patient demographics, pathology details and clinical outcomes of patients donating 
tumor samples to this study.  
Cohort Total Sunitinib naive Sunitinib 
treated
Number of patients 46 23 23 
Age, median (IQR) a 65.3 (59.0-72.9) 67.5 (59.2-72.9) 63.0 (56.0-73.0)  
Male gendera 30 (65.2%) 14 (60.9%) 16 (69.6%) 
Fuhrman gradeb: 
1
2
3
4
 
0 
14 (30.4%) 
23 (50.0%) 
9 (19.6%) 
 
0 
4 (17.4%) 
11 (47.8%) 
8 (34.8%) 
 
0 
10 (43.5%) 
12 (52.2%) 
1 (4.3%) 
Stagea: 
T1
T2
T3
T4
  
1 (2.2%) 
6 (13.0%) 
33 (71.7%) 
6 (13.0%) 
  
0 
2 (8.7%) 
20 (87.0%) 
1 (4.3%) 
  
1 (4.3%) 
4 (17.4%) 
13 (56.5%) 
5 (21.7%) 
Gradec,d: 
Single
Multiple
 
26 (57.8%) 
19 (42.2%) 
 
18 (81.8%) 
4 (18.2%) 
 
8 (34.8%) 
15 (65.2%) 
Multiregion samplinga: 
Protein
RNA
DNA
 
44 (95.7%) 
36 (78.3%) 
42 (91.3%) 
 
22 (95.7%) 
18 (78.3%) 
21 (91.3%) 
 
22 (95.7%) 
18 (78.3%) 
21 (91.3%) 
VHL statusa: 
Mutation
Wild type
 
33 (71.7%) 
13 (28.3%) 
 
18 (78.3%) 
5 (21.7%) 
 
15 (65.2%) 
8 (34.8%) 
Number of metastatic sitesa: 
1
2
3
  
22 (47.8%) 
18 (39.1%) 
6 (13.0%) 
  
14 (60.9%) 
7 (30.4%) 
2 (8.7%) 
  
8 (34.8%) 
11 (47.8%) 
4 (17.4%) 
Heng classificationa: 
Intermediate
Poor
Missing data
 
25 (54.3%) 
19 (41.3%) 
2 (4.3%) 
 
14 (60.9%) 
7 (30.4%) 
2 (8.7%) 
 
11 (47.8%) 
12 (52.2%) 
0 
1st line TKIe N/A 12 (52.2%) N/A 
Median overall survival, months 
(IQR)a 
15.9 
(9.0-25.9) 
12.2 
(6.7-19.4) 
23.0 
(13.6-30.0) 
IQR=interquartile range 
N/A=not applicable 
P-values comparing sunitinib naive and sunitinib treated patients: aP>0.05; bP=0.02; cP=0.002 
d1 sunitinib naive patient had inadequate tissue for grade analysis but enough tissue for multiregion sampling for 
RNA analysis only. Therefore denominator is 45 samples in total, 22 for sunitinib naïve patients and 23 for sunitinib 
treated patients. 
enumber of sunitinib naive patients who had post-nephrectomy TKIs. 
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Table 2. Details of individual patient clustering of DNA copy number variation and RNA 
expression. Black shaded boxed denote clustering for the indicated analysis for multiple samples 
from an individual patient. 
DNA Copy Number Variation Clustering 
 
PATIENT NUMBER OF DNA SAMPLES PER PATIENT UNSUPERVISED 
STROMAL 
GENES 
DRIVER 
MUTATION 
GENES 
HYPOXIA  
GENES 
Un
tr
ea
te
d 
BB070193 3  
BB090363 2  
BB090175 4  
BB100186 3  
BB100333 3  
BB100486 3  
RN000010 4  
RN000003 2  
RN000006 3  
RN000027 3  
RN000028 5  
RN000035 3  
RN000060 3  
RN000065 3  
RN000086 3  
RN000095 3  
RN000147 4  
RN000160 3  
RN000173 3 
RN000184 4  
RN000193 3  
Samples clustering 23/67 (34.3%) 
9/67 
(13.4%) 
20/67  
(29.9%) 
32/67 
(56.1%) 
Tr
ea
te
d 
SU01 3  
SU04 3  
SU05 3  
SU06 3  
SU09 3  
SU11 3  
SU13 3  
SU16 3  
SU19 3  
SU22 3  
SU23 3  
SU25 3  
SU26 3  
SU32 3  
SU36 3  
SU39 3  
Research. 
on June 5, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 26, 2015; DOI: 10.1158/1078-0432.CCR-15-0207 
 30
SU41 3  
SU46 3  
SU48 3  
SU49 2  
SU54 2  
Samples clustering 25/61 (41.0%) 
13/61 
(21.3%) 
8/61  
(13.1%) 
5/61 
(8.2%) 
P-value (untreated vs. treated; Fisher’s test) 0.44 0.25 0.032 5.465e-07
Gene Expression Clustering
 
PATIENT NUMBER OF RNA SAMPLES PER PATIENT UNSUPERVISED 
STROMAL 
GENES 
DRIVER 
MUTATION 
GENES 
HYPOXIA 
GENES 
Un
tr
ea
te
d 
BB070193 2  
BB090363 3  
BB090175 3  
BB100186 2  
BB100322 3  
BB100333 3  
BB100486 2  
RN000010 2  
RN000003 2  
RN000006 2  
RN000026 2  
RN000027 2  
RN000028 2  
RN000035 2  
RN000065 3  
RN000160 2  
RN000173 3  
RN000184 3  
Samples clustering 26/43 (60.5%) 
21/43
(48.9%) 
8/43 
(18.6) 
15/43 
(34.9%) 
Tr
ea
te
d 
SU01 8  
SU04 4  
SU05 2  
SU09 3  
SU11 8  
SU16 2  
SU17 5  
SU19 4  
SU22 7  
SU23 4  
SU25 4  
SU26 5  
SU32 2  
SU39 3  
SU41 2  
SU46 4  
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SU48 4  
SU49 2  
Samples clustering 48/73 (65.8%) 
19/73 
(26.0%) 
0/73  
(0%) 
18/73 
(24.7%) 
P-value (untreated vs. treated; Fisher’s test) 0.69 0.016 0.006 0.29
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